Ravn J, Scharff A, Aaskoven O
Pharmakopsychiatr Neuropsychopharmakol. 1980 Jan;13(1):34-40. doi: 10.1055/s-2007-1019608.
Chlorprothixene was the first neuroleptic of the thioxanthene group and was marketed in 1959 under the trade names of Taractan and Truxal. Since then 20 years have passed and the authors were of the opinion that it would be opportune to study the literature published during these 20 years. They perused 801 publications, hereof 542 clinical works. Of these clinical works 109 were suited for statistical analysis. They represented 7109 patients. The other publications comprise 4378 patients which means that all the literature studied consists of a total of 11487 patients. The chlorprothixene proved to be a broad-spectrum neuroleptic with good therapeutic effects. Side effects, especially the extrapyramidal symptoms, appeared only seldom. Among the 11487 patients only 1.02% showed extrapyramidal symptoms and of these only 0.05% had tardive dyskinesias. Sme evidence seems to exist that these are schizophrenic patients showing extrapyramidal symptoms, without having received neuroleptics. It is the authors' opinion that chlorprothixene is still a neuroleptic of topical interest.
氯普噻吨是硫杂蒽类的首个抗精神病药物，于1959年以Taractan和Truxal的商品名上市。自那时起已过去20年，作者认为此时研究这20年间发表的文献恰逢其时。他们研读了801篇出版物，其中542篇为临床研究。在这些临床研究中，109篇适合进行统计分析。这些研究涵盖了7109名患者。其他出版物涉及4378名患者，这意味着所研究的全部文献共计11487名患者。氯普噻吨被证明是一种具有良好治疗效果的广谱抗精神病药物。副作用，尤其是锥体外系症状，很少出现。在11487名患者中，仅有1.02%出现锥体外系症状，其中仅有0.05%患有迟发性运动障碍。似乎有证据表明，这些出现锥体外系症状的患者是精神分裂症患者，且未接受过抗精神病药物治疗。作者认为氯普噻吨仍是一种具有当前研究价值的抗精神病药物。
